Buscar
Mostrando ítems 1-10 de 15
Efeitos da buspirona em modelos animais de discinesia tardia
(Brasil, 1999)
In the last two centuries, the knowledgement about the central nervous systems increased enormously, making possible the treatment of patients who suffer of all sort of central nervous systems’ diseases. One of this diseases ...
Efeito da dieta hiperlipídica e da tintura de Valeriana officinalis no modelo crônico de discinesia orofacial induzida por haloperidol em ratos
(Universidade Federal de Santa MariaBRBioquímicaUFSMPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica, 2006-10-30)
Haloperidol-induced orofacial dyskinesia (OD) is a putative animal model of tardive dyskinesia (TD) whose pathophysiology has been related to an increase in dopamine
turnover, reduction in gabaergic neurotransmission and ...
Efeito do decocto de Bauhinia forficata sobre parâmetros comportamentais e metabólicos em ratos tratados com haloperidol
(Universidade Federal de Santa MariaBRBioquímicaUFSMPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica, 2012-09-27)
Schizophrenia is a psychiatric disorder that affects 1% of world population and its pharmacologic treatment consists in the use of antipsychotics. It is known that chronic treatment with classical antipsychotics, such as ...
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos
(Universidade Federal de Santa MariaBrasilFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCentro de Ciências da Saúde, 2017-02-18)
Fluphenazine is a typical antipsychotic used for the treatment of schizophrenia. However, its chronic use has been related to the appearance of extrapyramidal side effects, such as tardive dyskinesia (TD). Studies suggest ...
Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations
(Wiley-blackwellHobokenEUA, 2013)
Aminochrome as new preclinical model to find new pharmacological treatment that stop the development of parkinsons disease
(Bentham Science Publishers B.V., 2016)
© 2016 Bentham Science Publishers.The pharmacological treatment of Parkinsońs disease (PD) is limited to dopamine agonists and anti-cholinergic drugs that do not stop the progress of disease. LDopa was introduced to the ...
Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson's Disease
(Bentham Science, 2016)
The pharmacological treatment of Parkinson's disease (PD) is limited to dopamine agonists and anti-cholinergic drugs that do not stop the progress of disease. L-Dopa was introduced to the treatment in 1967; this drug is ...
Extrapyramidal Side Effects of AntiemeticsExtrapiramidalismo por antieméticosReações extrapiramidais causadas por antieméticos
(Universidad Militar Nueva Granada, 2020)
Extrapyramidal Side Effects of AntiemeticsExtrapiramidalismo por antieméticosReações extrapiramidais causadas por antieméticos
(Universidad Militar Nueva Granada, 2020)
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease
(Adis Int Ltd, 2016-08)
Dopamine agonists are well-established symptomatic medications for treating early and advanced Parkinson disease (PD). Piribedil was one of the first agonists to be marketed (1969) and is widely used as an extended-release ...